Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

Levy PD, Nandyal D, Welch RD, Sun JL, Pieper K, Ghali JK, Fonarow GC, Gheorghiade M, O'Connor CM.

Am Heart J. 2010 Feb;159(2):222-230.e2. doi: 10.1016/j.ahj.2009.11.009. Erratum in: Am Heart J. 2010 Jul;160(1):208.

PMID:
20152220
2.
3.
4.

Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.

Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H; JCARE-CARD Investigators..

Hypertens Res. 2010 Mar;33(3):197-202. doi: 10.1038/hr.2009.199. Epub 2009 Dec 4.

PMID:
19960016
5.

Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC.

Am Heart J. 2008 Oct;156(4):662-73. doi: 10.1016/j.ahj.2008.04.030.

PMID:
18926148
6.

Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.

Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators..

J Card Fail. 2007 Nov;13(9):722-31.

PMID:
17996820
7.
8.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.

Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.

Am Heart J. 2007 Jun;153(6):1064-73.

PMID:
17540211
9.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators..

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
10.
11.

Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.

Hess G, Preblick R, Hill J, Plauschinat CA, Yaskin J.

Congest Heart Fail. 2009 Jul-Aug;15(4):170-5. doi: 10.1111/j.1751-7133.2009.00092.x.

12.

Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF).

Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals..

Arch Intern Med. 2007 Jul 23;167(14):1493-502.

PMID:
17646603
13.

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals..

J Am Coll Cardiol. 2007 Aug 21;50(8):768-77. Epub 2007 Aug 6.

14.

Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.

O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M.

J Card Fail. 2005 Apr;11(3):200-5.

PMID:
15812748
15.

Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials.

Jong P, Demers C, McKelvie RS, Liu PP.

J Am Coll Cardiol. 2002 Feb 6;39(3):463-70.

16.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

17.

Heart failure: is there a role for angiotensin II receptor blockers?

Boucher M, Ma J.

Issues Emerg Health Technol. 2002 Sep;(38):1-4.

PMID:
12243202
18.

Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.

McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV.

Circulation. 2006 Jun 6;113(22):2572-8. Epub 2006 May 30.

19.

Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.

Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen ZM, Collins R, Flather M, Franzosi MG, Kjekshus J, Køber L, Liu LS, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S.

J Am Coll Cardiol. 2000 Jun;35(7):1801-7.

20.

Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.

Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR.

J Am Coll Cardiol. 2004 Jun 2;43(11):2036-43.

Supplemental Content

Support Center